tradingkey.logo

Overall Survival Primary Endpoint Met In Corcept’S Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer

ReutersJan 22, 2026 1:19 PM

- Corcept Therapeutics Inc CORT.O:

  • OVERALL SURVIVAL PRIMARY ENDPOINT MET IN CORCEPT’S PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

  • CORCEPT THERAPEUTICS INC - DATA SHOW 35% REDUCTION IN RISK OF DEATH

  • CORCEPT THERAPEUTICS INC - PHASE 3 ROSELLA TRIAL MEETS OVERALL SURVIVAL ENDPOINT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI